NCE2/UBE2F antibody | knockout validation | Abcam ab185234

This is a knockout-validated antibody summary, based on the publication "The CUL5 Ubiquitin Ligase Complex Mediates Resistance to CDK9 and MCL1 Inhibitors in Lung Cancer Cells", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

NCE2/UBE2F antibody | knockout validation | Abcam ab185234 figure 1
Figure 1. Western blotting validating loss of CUL5 and UBE2F protein in the three CUL5-KO clones and one UBE2F-KO clone, respectively. GAPDH, loading control. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Abcam

Antibody: NCE2/UBE2F

Catalog number: ab185234

Summary: Rabbit monoclonal IgG against a recombinant fragment within human NCE2/UBE2F (aa 1-150, N terminal). Reacts with human by western blot, immunohistochemistry (paraffin), flow cytometry and immunocytochemistry/immunofluorescence.

Validation Method

Western blot

Sample

Parental and UBE2F-KO LK2 cells.

Primary incubation

Manufacturer’s recommended dilutions were used.

Secondary incubation

1:10,000 dilution donkey anti-rabbit 680 (925–68023; LI-COR) or donkey anti-rabbit 800 (925–32213; LI-COR).

Detection

Blots were imaged on an Odyssey CLx Imaging System (LI-COR).

References
  1. Kabir S, Cidado J, Andersen C, Dick C, Lin P, Mitros T, et al. The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells. elife. 2019;8: pubmed publisher